XML 52 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisition of Insight (Details Narrative)
$ in Thousands
 1 Months Ended 3 Months Ended
Jan. 31, 2020
USD ($)
Number
shares
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Sale of common shares   $ 71,746 $ 7,597  
Discount rate   11.34%    
Operating lease, right use of asset [1]   $ 3,397   $ 3,397
Fair value of contingent consideration   $ 1,100    
Milestone Contingent Consideration [Member]        
Payments for milestones $ 6,000      
Discount rate 8.00%      
Credit and risk-adjusted discount rate 47.00%      
Cash Holdback [Member]        
Cash $ 600     $ 6,400
Sale of common shares $ 600      
Stock Holdback [Member]        
Number of common stock, shares issued | shares 229,885      
Stock Holdback One [Member]        
Number of common stock, shares issued | shares 1,900,000      
Clinical Trial and Data Publication Milestone [Member] | Milestone Contingent Consideration [Member]        
Payments for milestones $ 1,500      
CMS Specified Lung Cancer [Member] | Milestone Contingent Consideration [Member]        
Payments for milestones 3,000      
CMS Reimbursement Milestones [Member] | Milestone Contingent Consideration [Member]        
Payments for milestones 1,500      
Merger Agreements [Member]        
Cash 7,000      
Sale of common shares 5,000      
Merger consideration 11,400      
Common stock delivered average value $ 5,000      
Trading days | Number 5      
Fair value of intangible asset $ 14,700      
Discount rate 35.00%      
Acquisition of offsetting $ 1,300      
Estimated useful lives of amortization 5 years      
Operating lease, right of use liability $ 500      
Operating lease, right use of asset 500      
Deferred tax liabilities 1,300      
Merger Agreements [Member] | Laboratory Machinery and Equipment [Member]        
Fair value of intangible asset $ 100      
[1] Oncocyte recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Notes 5 and 14).